About our Company

Our Mission

  • Impeto Medical is a privately owned medical device company created in June 2005. Its corporate headquarters are located in Paris, France. The company is also present in San Diego, CA, USA and in Beijing, China.

  • Our goal is to provide the medical community with screening tests to face epidemically spreading metabolic disorders and their complications.
  • By providing less invasive, faster and less costly procedures, we enable physicians to screen larger patient populations and to detect diseases complications earlier.
  • We build value for our investors through constant innovation based on clinical research as well as focus on priority medical issues.


The SUDOCAN® device is covered by the following patents:

  • “Electrophysiological analysis system and method” (US Patent No. US 8965497B2, European Patent No. EP 1898783B1),

  • “Electrophysiological analysis system” (US Patent No. US 8655443B2, European Patent No. EP 2124736B1),
  • “Assessment of sudomotor function for peripheral diabetic neuropathy evaluation” (US Patent No. US 8934954B2),
  • “Improved electrophysiological analysis system” (US Patent No. US 9636036B2, European Patent No. EP 2890294B1).

Certification System
ISO 13485:2016

Impeto Medical SAS

2 rue Maurice Hartmann, 92130 Issy Les Moulineaux
Tel: +33 (0)7 87 20 32 03
Email: info@impeto-medical.com

The advantage of
Neuropathy Early Detection

An innovative device for early detection and follow-up
of Autonomic and Small Fiber Neuropathy.

Simple results obtained in 3 minutes.